alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2021278EN.01006901.xml

| 12.7.2021 | EN | Official Journal of the European Union | C 278/69 |
| --- | --- | --- | --- |

12.7.2021

EN

Official Journal of the European Union

C 278/69

---

Action brought on 27 May 2021 — Bodegas Beronia v EUIPO — Bodegas Carlos Serres (ALEGRA DE BERONIA)

(Case T-298/21)

(2021/C 278/93)

Language in which the application was lodged: Spanish

Parties

Applicant: Bodegas Beronia, SA (La Rioja, Spain) (represented by: J. Mora Cortés, lawyer)

Defendant: European Union Intellectual Property Office (EUIPO)

Other party to the proceedings before the Board of Appeal: Bodegas Carlos Serres, SL (La Rioja)

Details of the proceedings before EUIPO

Applicant for the trade mark at issue: Applicant before the General Court

Trade mark at issue: Application for EU word mark ALEGRA DE BERONIA — Application for registration No 18 012 451

Procedure before EUIPO: Opposition proceedings

Contested decision: Decision of the First Board of Appeal of EUIPO of 12 March 2021 in Case R 2013/2020-1

Form of order sought

The applicant claims that the General Court should:

| — | annul the contested decision, in so far as the appeal in Case R 2013/2020-1 was dismissed and registration of EU trade mark No 18 012 451 ALEGRA DE BERONIA (word mark) was refused in respect of all the goods at issue; |
| --- | --- |

—

annul the contested decision, in so far as the appeal in Case R 2013/2020-1 was dismissed and registration of EU trade mark No 18 012 451 ALEGRA DE BERONIA (word mark) was refused in respect of all the goods at issue;

| — | order EUIPO to pay the costs. |
| --- | --- |

—

order EUIPO to pay the costs.

Plea in law

| — | Infringement of Article 8(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council of 14 June 2017 on the European Union trade mark. |
| --- | --- |

—

Infringement of Article 8(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council of 14 June 2017 on the European Union trade mark.

---
#### HAUGH, h/w v. PA LCB

1985 CD 2016

Commonwealth Court of Pennsylvania.

10/04/2017

Liquor Control Board, 16 SU 841

Dismissed
**EXHIBIT 31.2**

 

**Certification of Chief Financial Officer**

**Pursuant toSection 302 of the Sarbanes-Oxley Act of 2002**

 

I,James E. Skinner, certify that:

 

1.     I have reviewed this amendment to thequarterly report on Form 10-Q/A of The Neiman Marcus Group, Inc.;

 

2.     Based on my knowledge, this report does notcontain any untrue statement of a material fact or omit to state a materialfact necessary to make the statements made, in light of the circumstances underwhich such statements were made, not misleading with respect to the periodcovered by this report;

 

3.     Based on my knowledge, the financialstatements, and other financial information included in this report, fairlypresent in all material respects the financial condition, results of operationsand cash flows of the registrant as of, and for, the periods presented in thisreport;

 

4.     The registrant’s other certifying officerand I are responsible for establishing and maintaining disclosure controls andprocedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for theregistrant and have:

 

a)     designed such disclosure controls and procedures, or caused suchdisclosure controls and procedures to be designed under our supervision, toensure that material information relating to the registrant, including itsconsolidated subsidiaries, is made known to us by others within those entities,particularly during the period in which this report is being prepared;

 

b)    evaluated the effectiveness of the registrant’s disclosurecontrols and procedures and presented in this report our conclusions about theeffectiveness of the disclosure controls and procedures, as of the end of theperiod covered by this report based on such evaluation; and

 

c)     disclosed in this report any change in the registrant’s internalcontrol over financial reporting that occurred during the registrant’s mostrecent fiscal quarter (the registrant’s second fiscal quarter) that hasmaterially affected, or is reasonably likely to materially affect, theregistrant’s internal control over financial reporting; and

 

5.     The registrant’s other certifying officerand I have disclosed, based on our most recent evaluation of internal controlover financial reporting, to the registrant’s auditors and the audit committeeof the registrant’s board of directors (or persons performing the equivalentfunctions):

 

a)     all significant deficiencies and material weaknesses in thedesign or operation of internal control over financial reporting which arereasonably likely to adversely affect the registrant’s ability to record,process, summarize and report financial information; and

 

b)    any fraud, whether or not material, that involves management orother employees who have a significant role in the registrant’s internalcontrol over financial reporting.

 

Date:May 27, 2005

 

 
|   | /s/    JAMES E. SKINNER            |
|--------|--------------------------------------------------------|
|   | **James E.  Skinner**                                  |
|   | **Senior  Vice President and Chief Financial Officer** |

 

1

----
|
|

|Energy Market and Economic Impacts of H.R. 2454, the American Clean Energy and Security Act of 2009                                                                                                       
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|Table B2. Assumed International Abatement Demand, Excluding the United States (million metric tons carbon dioxide equivalent).  Need help, contact the National Energy Information Center at 202-586-8800.
|Table B2. Assumed International Abatement Demand, Excluding the United States (million metric tons carbon dioxide equivalent).  Need help, contact the National Energy Information Center at 202-586-8800.
|Table B2. Assumed International Abatement Demand, Excluding the United States (million metric tons carbon dioxide equivalent).  Need help, contact the National Energy Information Center at 202-586-8800.
|Table B2. Assumed International Abatement Demand, Excluding the United States (million metric tons carbon dioxide equivalent).  Need help, contact the National Energy Information Center at 202-586-8800.
Document

AMENDMENT No. 1


EXECUTIVE EMPLOYMENT AGREEMENT


This Amendment No. 1 is made as of July 8, 2021, by and between Robert D. Starr (“Executive”) and Kaman Corporation (“Kaman” or “Company”).


WITNESSETH:


WHEREAS, the Company and Executive previously entered into an Executive Employment Agreement originally effective as of November 18, 2014 (the “Employment Agreement”); and


WHEREAS, the parties desire to further amend the Employment Agreement in accordance with its terms and subject to the provisions of this Amendment;


NOW THEREFORE, in consideration of the mutual promises contained in this Amendment, Company and Executive agree as follows:


1.Section 8(d)(3) of the Employment Agreement is hereby amended in its entirety to read as follows:


“(3) an amount equal to the product of two times the sum of (i) the Executive’s then current Base Salary and (ii) the annual bonus at the current target award percentage of Base Salary, payable in a single lump sum within 30 days after employment termination. Notwithstanding the foregoing, if the Executive terminates employment within two years of his Retirement Eligibility Date, the lump sum amount described in the immediately preceding sentence shall be reduced by multiplying it by a fraction, the numerator of which is the number of days from the Executive’s employment termination date until the Retirement Eligibility Date, and the denominator of which is 730.”


2.Capitalized terms not otherwise defined in this Amendment shall have the meaning ascribed to them in the Employment Agreement.


3.Except as expressly modified herein, all provisions of the Employment Agreement shall remain in full force and effect.


In Witness Whereof, the Company and the Executive have executed this Amendment as of the day and year first above written.




															
	KAMAN CORPORATION   		ROBERT D. STARR
					
	By:	/s/ Ian K. Walsh		/s/ Robert D. Starr
		Ian K. Walsh			
	Its:	Chairman, President and Chief Executive Officer
No. 12-29.

#### McPeters *v.*Edwards, Individually and in His Official Capacity as the District Judge of the 9th Dis*884trict Court, Montgomery County, Texas, et al.

C. A. 5th Cir. Certiorari denied.
# C_2022326EN.01002802.xml

| 29.8.2022 | EN | Official Journal of the European Union | C 326/28 |
| --- | --- | --- | --- |

29.8.2022

EN

Official Journal of the European Union

C 326/28

---

Action brought on 12 July 2022 — Vanhove v EUIPO — Aldi Einkauf (bistro Régent)

(Case T-437/22)

(2022/C 326/39)

Language in which the application was lodged: English

Parties

Applicant: Vanhove (Bordeaux, France) (represented by: N. Castagnon, lawyer)

Defendant: European Union Intellectual Property Office (EUIPO)

Other party to the proceedings before the Board of Appeal: Aldi Einkauf SE & Co. OHG (Essen, Germany)

Details of the proceedings before EUIPO

Applicant of the trade mark at issue: Applicant before the General Court

Trade mark at issue: Application for European Union figurative mark bistro Régent — Application for registration No 18 136 358

Procedure before EUIPO: Opposition proceedings

Contested decision: Decision of the Fifth Board of Appeal of EUIPO of 18 May 2022 in Case R 1113/2021-5

Form of order sought

The applicant claims that the Court should:

| — | annul the contested decision; |
| --- | --- |

—

annul the contested decision;

| — | grant the European Union trade mark registration in respect of the designated ‘wines’ in Class 33; |
| --- | --- |

—

grant the European Union trade mark registration in respect of the designated ‘wines’ in Class 33;

| — | order EUIPO and, in case of an intervention, also the intervener to pay the costs. |
| --- | --- |

—

order EUIPO and, in case of an intervention, also the intervener to pay the costs.

Pleas in law

| — | Infringement of Article 47(2) and (3) of Regulation (EU) 2017/1001 of the European Parliament and of the Council; |
| --- | --- |

—

Infringement of Article 47(2) and (3) of Regulation (EU) 2017/1001 of the European Parliament and of the Council;

| — | Infringement of Article 8(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council. |
| --- | --- |

—

Infringement of Article 8(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council.

---
# Federal Student Loans

- Biden-Harris Administration Announces Nearly 5.5 Million Borrowers Are Enrolled in the SAVE Plan The Biden-Harris Administration released data today  showing that nearly 5.5 million borrowers are now enrolled in the Saving on a  Valuable Education (SAVE) Plan, including 2.9 million who have $0 payments. All  other borrowers enrolled in SAVE are saving an estimated $102 a month ($1,224 a  year) compared to what they would have paid on the Revised Pay As You Earn  (REPAYE) plan.
- Extended Closed School Discharge Will Provide 115K Borrowers from ITT Technical Institute More Than $1.1B in Loan Forgiveness Today, the U.S. Department of Education announced it will make $1.1 billion in closed school discharges available to an additional 115,000 borrowers who attended the now-defunct ITT Technical Institute (ITT). This decision is based on a new review of the problems leading up to ITT's closure. These borrowers did not complete their degree or credential and left ITT on or after March 31, 2008.
- Over 323,000 Federal Student Loan Borrowers to Receive $5.8 Billion in Automatic Total and Permanent Disability Discharges Over 323,000 borrowers who have a total and permanent disability (TPD) will receive more than $5.8 billion in automatic student loan discharges due to a new regulation announced today by the U.S. Department of Education.  The change will apply to borrowers who are identified through an existing data match with the Social Security Administration (SSA).
# C_2023189EN.01003101.xml

| 30.5.2023 | EN | Official Journal of the European Union | C 189/31 |
| --- | --- | --- | --- |

30.5.2023

EN

Official Journal of the European Union

C 189/31

---

Judgment of the General Court of 19 April 2023 — Zitro International v EUIPO — e-gaming (Smiley wearing a top hat)

(Case T-491/22) (1)

(EU trade mark - Opposition proceedings - Application for an EU figurative mark representing a smiley wearing a top hat - Earlier EU figurative mark representing a fantasy figure - Relative ground for refusal - Article 8(1)(b) of Regulation (EU) 2017/1001)

(2023/C 189/41)

Language of the case: English

Parties

Applicant: Zitro International Sàrl (Luxembourg, Luxembourg) (represented by: A. Canela Giménez, lawyer)

Defendant: European Union Intellectual Property Office (represented by: D. Stoyanova-Valchanova and D. Gája, acting as Agents)

Other party to the proceedings before the Board of Appeal of EUIPO: e-gaming s. r. o. (Prague, Czech Republic)

Re:

By its action brought under Article 263 TFEU, the applicant seeks annulment of the decision of the Fourth Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 30 May 2022 (Case R 2005/2021-4).

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Zitro International Sàrl to bear its own costs; |
| --- | --- |

2.

Orders Zitro International Sàrl to bear its own costs;

| 3. | Orders the European Union Intellectual Property Office (EUIPO) to bear its own costs. |
| --- | --- |

3.

Orders the European Union Intellectual Property Office (EUIPO) to bear its own costs.

---

(1)  OJ C 380, 3.10.2022.

---
# C_2022284EN.01004402.xml

| 25.7.2022 | EN | Official Journal of the European Union | C 284/44 |
| --- | --- | --- | --- |

25.7.2022

EN

Official Journal of the European Union

C 284/44

---

Action brought on 16 May 2022 — Biogen Netherlands v Commission

(Case T-269/22)

(2022/C 284/61)

Language of the case: English

Parties

Applicant: Biogen Netherlands BV (Badhoevedorp, Netherlands) (represented by: C. Schoonderbeek, lawyer)

Defendant: European Commission

Form of order sought

The applicant claims that the Court should:

| — | annul the decision C(2022)3253 (final) of the European Commission of 13 May 2022 granting marketing authorisation under Regulation (EC) No 726/2004 (1) for ‘Dimethyl fumerate Polpharma — dimethyl fumarate’, a medicinal product for human use; and |
| --- | --- |

—

annul the decision C(2022)3253 (final) of the European Commission of 13 May 2022 granting marketing authorisation under Regulation (EC) No 726/2004 (1) for ‘Dimethyl fumerate Polpharma — dimethyl fumarate’, a medicinal product for human use; and

| — | order the Commission to pay the costs. |
| --- | --- |

—

order the Commission to pay the costs.

Pleas in law and main arguments

In support of the action, the applicant relies on two pleas in law.

| 1. | First plea in law, alleging failure to observe the system of Directive 2001/83/EC (2) in relation to the rules on regulatory data protection, including Article 6(1) of that Directive, and the obligations of generic applicants under Article 10(1) of that Directive. |
| --- | --- |

1.

First plea in law, alleging failure to observe the system of Directive 2001/83/EC (2) in relation to the rules on regulatory data protection, including Article 6(1) of that Directive, and the obligations of generic applicants under Article 10(1) of that Directive.

| 2. | Second plea in law, alleging failure to recognize the consequences of the Opinion of the Committee for Medicinal Products for Human Use of 11 November 2021 for the question whether the marketing authorisation for the medicinal product Fumaderm was capable of commencing a global marketing authorisation for the medicinal product Tecfidera in accordance with Article 6(1), second subparagraph, of Directive 2001/83/EC. |
| --- | --- |

2.

Second plea in law, alleging failure to recognize the consequences of the Opinion of the Committee for Medicinal Products for Human Use of 11 November 2021 for the question whether the marketing authorisation for the medicinal product Fumaderm was capable of commencing a global marketing authorisation for the medicinal product Tecfidera in accordance with Article 6(1), second subparagraph, of Directive 2001/83/EC.

---

(1)  Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ 2004, L 136, p. 1).

(2)  Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001, L 311, p. 67).

---
Exhibit 18.1







December 1, 1999



The Neiman Marcus Group, Inc.
27 Boylston Street
Chestnut Hill, MA  02467


Dear Sirs/Madam:

At your request, we have read the description included in your
Quarterly Report on Form 10-Q to the Securities and Exchange
Commission for the quarter ended October 30, 1999, of the
facts relating to a change in accounting principle from last-
in-first-out retail to first-in-first-out retail.  We believe,
on the basis of the facts so set forth and other information
furnished to us by appropriate officials of The Neiman Marcus
Group, Inc. (the "Company"), that the accounting change
described in your Form 10-Q is to an alternative accounting
principle that is preferable under the circumstances.

We have not audited any consolidated financial statements of
the Company and its consolidated subsidiaries as of any date
or for any period subsequent to July 31, 1999.  Therefore, we
are unable to express, and we do not express, an opinion on
the facts set forth in the above-mentioned Form 10-Q, on the
related information furnished to us by officials of the
Company, or on the financial position, results of operations,
or cash flows of the Company and its consolidated subsidiaries
as of any date or for any period subsequent to July 31, 1999.


Yours truly,


S/ Deliotte & Touche LLP
Deloitte & Touche LLP
##### 



Exhibit 32.1 CERTIFICATION PURSUANT
TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Amendment No.1 to this Quarterly Report of Mayors
Jewelers, Inc. (the Company) on Form 10-Q/A for the thirteen weeks ended
December 27, 2003 as filed with the Securities and Exchange Commission on the
date hereof (the Report), I, Thomas A. Andruskevich, Chairman of the Board,
President and Chief Executive Officer of the Company, certify, pursuant to 18
U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley
Act of 2002 that:  (1)
    
    The Report fully complies with the requirements of section 13(a) or 15(d)
of the Securities Exchange Act of 1934; and(2)
    
    The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the
Company. Date:
January 7, 2005/s/ Thomas A. AndruskevichThomas A. AndruskevichChairman of the Board, President and Chief Executive Officer
<TABLE> <S> <C>

<ARTICLE>                     5
       
<S>                             <C>
<PERIOD-TYPE>                  3-MOS
<FISCAL-YEAR-END>                              MAR-31-1998
<PERIOD-END>                                   JUN-30-1997
<CASH>                                         506,432
<SECURITIES>                                   140,000
<RECEIVABLES>                                  2,138,100
<ALLOWANCES>                                   (513,219)
<INVENTORY>                                    0
<CURRENT-ASSETS>                               2,713,724
<PP&E>                                         4,093,161
<DEPRECIATION>                                 (1,311,015)
<TOTAL-ASSETS>                                 12,898,849
<CURRENT-LIABILITIES>                          5,212,781
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       211,200
<OTHER-SE>                                     16,125,896
<TOTAL-LIABILITY-AND-EQUITY>                   12,898,849
<SALES>                                        2,242,147
<TOTAL-REVENUES>                               2,242,147
<CGS>                                          1,716,820
<TOTAL-COSTS>                                  2,671,928
<OTHER-EXPENSES>                               2,349
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             76,131
<INCOME-PRETAX>                                0
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                            (508,261)
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   (508,261)
<EPS-PRIMARY>                                  (.03)
<EPS-DILUTED>                                  0
        

</TABLE>
ex_258920.htm


Exhibit 10.41


 


 


 


INDEMNIFICATION AGREEMENT


 


This Indemnification Agreement (the “Agreement”) is made by and between John Poss (the “Director”) and GB Sciences, Inc., a Nevada corporation (the “Company”) (jointly the “Parties”).


 


Recitals


 


	 	
			A.

				
			The Director is or was a member of the board of directors (the “Board”) of the Company.

			



 


 


	 	
			B.

				
			The Company does not at this time and has not at prior times during the Director’s service, had directors and officers and insurance (“D&O Insurance”).

			



 


Now therefore, in consideration of the obligations and promises made herein, the Parties agree as follows:


 


Agreement


 


	 	
			1.

				
			Willingness to Serve. The Director has been willing to serve on the Board, even in the absence of D&O Insurance, in exchange for the rights of indemnification set forth herein.

			



 


 


	 	
			2.

				
			Indemnification. The Company hereby indemnifies the Director against any loss, damage, cost or expense, including without limitation, legal fees, court costs, judgments, fines and amounts paid in settlement, actually and reasonably incurred by the Director, by reason of the fact he or she was a director, officer or agent of the Company, to the fullest extent allowed under Nevada law. For this right of indemnification to be effective with regard to any suit, action or proceeding, the Director must notify the Company within five calendar days of any suit, action or proceeding brought against the Director, and the Company must be allowed to defend or co-defend the suit, action or proceeding. In order for the Company to indemnify the Director against the payment of the settlement of any claim, the Company must have been given the opportunity to help negotiate and approve the settlement.

			



 


 


	 	
			3.

				
			Efforts to obtain Insurance. The Company agrees to continue to try to obtain D&O Insurance as finances and circumstances allow.

			



 


 


 


Dated: 11/12/2020                                  /s/   John Poss


GB SCIENCES, INC.


By: John Poss


Its: Chief Executive Officer


 


 


Dated: 11/12/2020                                   /s/ John Poss


                                           John Poss, Individual
No. D-2666.

#### In re Disbarment of Snyder.

Disbarment entered. [For earlier order herein, see 566 U. S. 960.]